Source: Annual Congress 2002 - Drug resistance in different areas
Disease area: Respiratory infections

Abstract

The aim of this study is to present treatment outcomes for patients, registered in 1999 in Latvia; the data of National TB register are used.
Cohort analysis for new pulmonary smear positive cases (586): cured and completed treatment – 74,1%, failure – 1,4%, treatment interruption – 3,9%, transferred out - 0,8%, died – 11,4%, multidrug resistant (MDR) TB – 8,4% and for smear and/or culture positive cases (919) – 77,9%, 1,0%, 4,5%, 1,0%, 7,6%, 8,0% respectively.
Cohort analysis for MDR TB cases after 24 months for smear positive cases (49): cured and completed treatment – 71,5%, failure – 16,3%, treatment interruption – 6,1%, died – 6,1%, and for smear and/or culture positive cases (74) – 73,0%, 12,2%, 9,4%, 5,4% respectively.
Cohort analysis including MDR TB cases results for new pulmonary smear positive cases (586): cured and completed treatment – 80,0%, failure – 2,7%, treatment interruption – 4,4%, transferred out - 0,9%, died – 12,0%, and for smear and/or culture positive cases (919) – 83,8%, 2,0%, 5,2%, 1,0%, 8,0% respectively.
Conclusions.
1.The new category for MDR TB cases for cohort analysis is established.
2. Full cohort analysis should be made after 2 years in countries with high level of MDR TB.

Rating:

Share or cite this content

Citations should be made in the following way:
V. Riekstina, V. Leimane, J. Leimans (Latvia). Cohort analysis in country with high level of multidrug resistant TB: how and when?. Eur Respir J 2002; 20: Suppl. 38, 2556

Member's Comments

No comment yet.

Related content which might interest you: Is it possible to achieve treatment success, recommended by WHO in country with high level of multidrug resistant TB? Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001 A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey Source: Eur Respir J, 51 (3) 1702571; 10.1183/13993003.02571-2017 Year: 2018 A tale of two settings: The role of the Beijing genotype in the rise of multidrug resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Development of multi-drug resistant tuberculosis among patients treated with category II regimen: A lung center of the Philippines experience Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Drug resistant tuberculosis: is it enough to justify low treatment success in Russia? Source: Eur Respir J 2001; 18: Suppl. 33, 175s Year: 2001 Study of drug resistance profile in Multidrug resistant tuberculosis (MDR TB) patients attending a tertiary care hospital at Mumbai. Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey Source: Eur Respir J 2011; 37: 222-224 Year: 2011 High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova Source: Eur Respir J 2014; 43: 1132-1141 Year: 2014 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Multi-drug resistant tuberculosis: a retrospective analysis of cases over 10 years in a low incidence setting Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Which is the level of education among TB and MDR TB patients about their disease? A patient‘s questionnaire Source: Eur Respir J 2006; 28: Suppl. 50, 588s Year: 2006 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013